1 |
Antidiabetic actions of GPR55 agonist Abn-CBD and sitagliptin in obese-diabetic high fat fed mice |
|
|
| Andrew G. McCloskey, Michael G. Miskelly, Ryan A. Lafferty, Peter R. Flatt, Aine M McKillop |
|
| Biochemical Pharmacology. 2022; : 115398 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
2 |
Stability of extemporaneously prepared sitagliptin phosphate solution |
|
|
| Abdel Naser Zaid, Yara Abu Zaaror, Aiman Kaddumi, Mashhour Ghanem, Nidal Jaradat, Tharaa Abu Salah, Sameera Siaj, Lana Omari, Girish Sailor |
|
| PLOS ONE. 2022; 17(3): e0262068 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
3 |
Circulating Dipeptidyl Peptidase Activity Is a Potential Biomarker for Inflammatory Bowel Disease |
|
|
| Simone E. Jaenisch, Catherine A. Abbott, Mark D. Gorrell, Peter Bampton, Ross N. Butler, Roger Yazbeck |
|
| Clinical and Translational Gastroenterology. 2022; 13(1): e00452 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
4 |
Synthesis, Characterization and Screening of Some Novel 2-Methyl-N'-
[(Z)-Substituted-Phenyl ethylidene] Imidazo [1, 2-a] Pyridine-3-Carbohy
drazide Derivatives as DPP-IV Inhibitors for the Treatment of Type 2 Diabetes
Mellitus |
|
|
| Prerana A. Chavan, Shailaja B. Jadhav |
|
| Letters in Drug Design & Discovery. 2022; 19(2): 160 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
5 |
Virtual Screening, Synthesis, and Biological Evaluation of Some Carbohydrazide Derivatives as Potential DPP-IV Inhibitors |
|
|
| Prerana B. Jadhav, Shailaja B. Jadhav, Mehrukh Zehravi, Mohammad S. Mubarak, Fahadul Islam, Philippe Jeandet, Sharuk L. Khan, Nazmul Hossain, Salma Rashid, Long Chiau Ming, Md. Moklesur Rahman Sarker, Mohd Fahami Nur Azlina |
|
| Molecules. 2022; 28(1): 149 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
6 |
HL-7 and HL-10 Peptides Stimulate Insulin Secretion in the INS-1 Insulinoma Cell Line through Incretin-Dependent Pathway and Increasing the Glucose Uptake in L6 Myoblast |
|
|
| Zahra Setayesh-Mehr, Mahdiye Poorsargol |
|
| International Journal of Peptide Research and Therapeutics. 2021; 27(4): 2231 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
7 |
Sitagliptin relieves diabetic nephropathy fibrosis via the MAPK/ERK signaling pathway |
|
|
| Shufeng Cheng, Liang Li, Chunquan Song, Huijing Jin, Shouguo Ma, Ping Kang |
|
| Minerva Endocrinologica. 2020; 45(3) |
|
| [Pubmed] [Google Scholar] [DOI] |
|
8 |
Pharmacological potential of novel agonists for FFAR4 on islet and enteroendocrine cell function and glucose homeostasis |
|
|
| A.G. McCloskey, M.G. Miskelly, P.R. Flatt, A.M. McKillop |
|
| European Journal of Pharmaceutical Sciences. 2020; 142: 105104 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
9 |
CRISPR/Cas9 gene editing demonstrates metabolic importance of GPR55 in the modulation of GIP release and pancreatic beta cell function |
|
|
| A.G. McCloskey, M.G. Miskelly, C.B.T. Moore, M.A. Nesbit, K.A. Christie, A.I. Owolabi, P.R. Flatt, A.M. McKillop |
|
| Peptides. 2020; 125: 170251 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
10 |
Alkaloid Fraction of Litsea glutinosa Leaves Provides an Important Precursor for Inhibition of Dipeptidyl Peptidase 4 Activity |
|
|
| S W Kisnawaty, P Nityasewaka, B A R Sukma, A V Putrinadia, T Ma’rifah, D G Tamtomo, D Indarto |
|
| IOP Conference Series: Materials Science and Engineering. 2019; 546(6): 062013 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
11 |
The effect of CD26-deficiency on dipeptidyl peptidase 8 and 9 expression profiles in a mouse model of Crohn's disease |
|
|
| Suncica Buljevic, Dijana Detel, Ester P. Pugel, Jadranka Varljen |
|
| Journal of Cellular Biochemistry. 2018; 119(8): 6743 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
12 |
Compare clinical efficacy between vildagliptin 100 mg and sitagliptin 100 mg in inadequate patients with sitagliptin 50 mg |
|
|
| Kuribayashi, N. |
|
| Therapeutic Research. 2012; 33(5): 703-710 |
|
| [Pubmed] [Google Scholar] |
|
13 |
Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): Crossover pilot study (J-VICTORIA study) |
|
|
| Masaya Sakamoto,Rimei Nishimura,Taiga Irako,Daisuke Tsujino,Kiyotaka Ando,Kazunori Utsunomiya |
|
| Cardiovascular Diabetology. 2012; 11(1): 92 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
14 |
Flavonoid rich fraction of Pilea microphylla (L.) attenuates metabolic abnormalities and improves pancreatic function in C57BL/KsJ-db/db mice |
|
|
| P. Bansal,P. Paul,G. Shankar,D. Munjal,P.G. Nayak,K.I. Priyadarsini,M.K. Unnikrishnan |
|
| Biomedicine & Preventive Nutrition. 2011; 1(4): 268 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
15 |
Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222 |
|
|
| Greene, R.J., Tu, H., Gibbs, J.P., Greg Slatter, J. |
|
| Xenobiotica. 2011; 41(11): 945-957 |
|
| [Pubmed] [Google Scholar] |
|
16 |
Flavonoid rich fraction of Pilea microphylla (L.) attenuates metabolic abnormalities and improves pancreatic function in C57BL/KsJ-db/db mice |
|
|
| Bansal, P., Paul, P., Shankar, G., Munjal, D., Nayak, P.G., Priyadarsini, K.I., Unnikrishnan, M.K. |
|
| Biomedicine and Preventive Nutrition. 2011; 1(4): 268-272 |
|
| [Pubmed] [Google Scholar] |
|
17 |
Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans |
|
|
| Ahrén, B., Schweizer, A., Dejager, S., Villhauer, E.B., Dunning, B.E., Foley, J.E. |
|
| Diabetes, Obesity and Metabolism. 2011; 13(9): 775-783 |
|
| [Pubmed] [Google Scholar] |
|
18 |
Clinical experience of a selective dipeptidyl peptidase IV inhibitor, vildagliptin |
|
|
| Tomioka, Y. |
|
| Therapeutic Research. 2011; 32(6): 841-849 |
|
| [Pubmed] [Google Scholar] |
|
19 |
Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans |
|
|
| B. Ahrén,A. Schweizer,S. Dejager,E. B. Villhauer,B. E. Dunning,J. E. Foley |
|
| Diabetes, Obesity and Metabolism. 2011; 13(9): 775 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
20 |
Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222 |
|
|
| Robert J. Greene,Hua Tu,John P. Gibbs,J. Greg Slatter |
|
| Xenobiotica. 2011; 41(11): 945 |
|
| [Pubmed] [Google Scholar] [DOI] |
|